Previous Device Burden: CGM falling off during exercise, unable to access phone and cannot hear alerts.
Favorite Eversense Benefit: “I don’t worry about wasting a sensor if I’m too sweaty for my CGM to stay on my skin.”
Help your patients live life uninterrupted.
Eversense E3 CGM System is the only CGM with 6 months of continuous glucose readings designed to reduce interruptions that stand in the way of optimal care.
Eversense E3 is designed to overcome the limitations of short-term CGM systems
#1 CGM in Survivability & Longevity1-3
Most Accurate in Low Glucose Ranges1-3
Most Dependable Detection Alerts1-3
Almost No Skin Reactions from Adhesive4
The Eversense difference.
Eversense E3 is an optimal choice for adults with diabetes on insulin
Eversense solves the real-life challenges of traditional CGMs.
If your patients are experiencing:
- Sensors falling or knocked off
- Sensors not lasting as long as expected
- Questioning accuracy of readings
- Alarm fatigue
- Skin irritation from adhesives
- False lows or compression lows
See how Eversense E3 outlasts and outperforms traditional CGMs.
Eversense E3
Traditional CGMs2,3
Sensor Lifetime
6 months
7-14 days
Survivability Rate at Lifetime Percentage
95%
68.3-80.5%
Sensor Technology
Fluorescent
Enzymatic
MAD (mg/dL) Severe Hypo-Range**
7.5
14.2-16
Essentially No Compression Lows
Yes
No
Drug Interference
Tetracycline and Mannitol
Acetaminophen, Hydroxyurea, Ascorbic acid (Vitamin C)
Annual Sensor Insertions
2
26-36
On body vibration alerts
Yes
No
Easy-on, Easy-off Transmitter
Yes*
No
Adhesive
Silicone-based
Acrylic-based
** 40-60 mg/dL for Eversense E3. < 54 mg/dL for all others
The CGM for real life.
Eversense E3 delivers real-life benefits to you and your patients. Download our guide to learn more about the types of patients who benefit most from our 6 month CGM system.
Getting started is easy.
Step One: Prescribe the Eversense E3 CGM System
Patient referrals can be made to Ascensia Diabetes Care by:
• Parachute Health
• Fax PIF, CMN, Chart Notes and Insurance Info
Step Two: Refer your patients to the Eversense Inserter Network
Our skilled medical professionals will manage:
• Insertion and removal procedures
• Billing
• Scheduling
Broad coverage for your patients
Eversense E3 is available to over 300 million covered lives in the U.S. Explore more details including Federally Funded plans and commercial plans.
The Eversense PASS Program
Eligible individuals can experience CGM for only $99†, now and in the future.
1. Senseonics. (2023) Eversense E3 Continuous Glucose Monitoring System User Guide. LBL-6002-01-001_Rev C
2. Dexcom. (2023) G7 User Guide. AW00078-10 Rev 002 MT-00078-10
3. Abbott. (2022) FreeStyle Libre 3 Flash Glucose Monitoring System User Manual. ART43911-001 Rev. B 06/22
4. Deiss D., et al. Real-World Safety of an Implantable Continuous Glucose Sensor Over Multiple Cycles of Use: A Post-Market Registry Study. Diabetes Technol & Ther, 2020, 22(1);48-52. DOI: 10.1089/dia.2019.0159.
* There is no glucose data generated when the transmitter is removed
† Offer does not apply to the insertion and removal procedures. The Eversense PASS Program has limitations on eligibility. Ascensia Diabetes Care reserves the right to change or terminate this program at any time without notice. The program benefit is capped per transaction. There may be instances in which out-of-pocket costs exceed what is detailed in the offer.
Disclaimer
The Eversense® E3 Continuous Glucose Monitoring (CGM) System is indicated for continually measuring glucose levels for up to 180 days in persons with diabetes age 18 and older. The system is indicated for use to replace fingerstick blood glucose (BG) measurements for diabetes treatment decisions. Fingerstick BG measurements are still required for calibration primarily one time a day after day 21, and when symptoms do not match CGM information or when taking medications of the tetracycline class. The sensor insertion and removal procedures are performed by a health care provider. The Eversense E3 CGM System is a prescription device; patients should talk to their health care provider to learn more.
For safety information click here.
Eversense, Eversense E3 Continuous Glucose Monitoring and the Eversense logo are trademarks of Senseonics, Incorporated. Ascensia, and the Ascensia Diabetes Care logo are trademarks and/or registered trademarks of Ascensia Diabetes Care Holdings AG. All other trademarks are properties of their respective owners and are used solely for informative purposes. No relationship or endorsement should be inferred or implied.
Apple Watch® is a product of Apple, Inc., and may be separately purchased from an authorized Apple retailer. Apple Watch is not included with the Eversense CGM System. Android is a trademark of Google LLC.
PP-SENS-E3-GBL-0066